Arcellx announces pre-clinical data presentation for aclx-002, a novel cd123-targeted universal car-t cell therapy for relapsed or refractory acute myeloid leukemia at the american association for cancer research annual meeting 2022

Foster city, calif., march 8, 2022 /prnewswire/ -- arcellx, inc. (nasdaq: aclx), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the upcoming presentation at the american association for cancer research annual meeting 2022 of pre-clinical data for aclx-002, a novel cd123-targeted universal car-t cell therapy for relapsed or refractory acute myeloid leukemia (aml).
ACLX Ratings Summary
ACLX Quant Ranking